Clinical Trial Update: Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma

View source ↗

Summary

Clinical trial update reporting effects of sunitinib (Sutent) on tumor vascularization and necrosis in patients with renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Renal Cell Cancer | Status: COMPLETED